June 22, 2010
The FDA has approved Namenda XR, an extended-release formulation of memantine HCl, for the treatment of moderate to severe dementia of the Alzheimer's type.
May 11, 2010
The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.
January 26, 2010
FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).
November 25, 2009
Eisai and Pfizer announced that the FDA has accepted for review the New Drug Application (NDA) for once-daily 23 mg Aricept (donepezil HCl extended release tablets) for the treatment of moderate to severe Alzheimer's disease (AD).
April 15, 2009
Pfizer and Medivation, Inc announced the initiation of a 12-month, Phase 3 trial of the investigational drug Dimebon in combination with donepezil HCl for the treatment of mild-to-moderate Alzheimer's disease (AD).